Lymphoma

Tisagenlecleucel, a groundbreaking CAR-T cell therapy, has shown remarkable potential in the treatment of relapsed or refractory follicular lymphoma (r/r FL).

Tisagenlecleucel, commercially known as Kymriah, is a groundbreaking CAR-T cell therapy that has revolutionized the treatment landscape for certain types of blood cancers.

Tisagenlecleucel (tisa-cel), a type of chimeric antigen receptor T-cell therapy (CAR-T), has emerged as a promising new treatment option for patients with relapsed or refractory DLBCL. In this article, we will provide a comprehensive overview of tisa-cel, including its mechanism of action, clinical trials, side effects, and potential future applications.

Tisagenlecleucel, a groundbreaking cellular immunotherapy, has revolutionized the treatment of certain types of cancer.

The approval of tisagenlecleucel (Kymriah) by the U.S. Food and Drug Administration (FDA) marks a significant milestone in the field of cancer treatment.

Tecartus, a groundbreaking CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences, targets CD19, a protein expressed on the surface of certain blood cancer cells.

Tecartus comes with a substantial price of approximately $373,000 per treatment.

Tecartus, a CD19-directed genetically modified autologous T cell immunotherapy, has revolutionized the treatment landscape for relapsed or refractory mantle cell lymphoma and B cell acute lymphoblastic leukemia.

On July 24, 2020, the FDA approved Tecatus for the treatment of relapsed/refractory mantle cell lymphoma (MCL) in adult patients, It is the first and only CAR-T therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) in adult patients.

In particular, Tecartus (brexucabtagene autoleucel), developed by Kite Pharma (now a subsidiary of Gilead Sciences), has shown promising results in treating relapsed or refractory MCL.

Approved by the FDA for its efficacy in treating relapsed or refractory mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (ALL), Tecartus represents a significant advancement in cancer treatment.